Bacterial infections in adult HIV-infected patients

HIV Clinical Trials

Volumn 6, Issue 4, 2005, Pages 213-228

  Nagappan, Vijayalakshmi ^a   Kazanjian, Powel ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

AIDS; Bacteria; HAART

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; ATOVAQUONE; AZITHROMYCIN; CD4 ANTIGEN; CLARITHROMYCIN; COTRIMOXAZOLE; MACROLIDE; MALOPRIM; PENTAMIDINE; PLACEBO; PNEUMOCOCCUS VACCINE; PYRROLE DERIVATIVE; RIFABUTIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIMICROBIAL ACTIVITY; BACTEREMIA; BACTERIAL INFECTION; BACTERIAL STRAIN; CATHETER INFECTION; CLINICAL FEATURE; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE ASSOCIATION; DRUG COST; DRUG EFFICACY; GASTROENTERITIS; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPETENCE; INFECTION RISK; INFLUENZA; INFORMATION RETRIEVAL; LYMPHOCYTE COUNT; MALIGNANT NEOPLASTIC DISEASE; MEDICAL LITERATURE; MEDLINE; MYCOBACTERIUM AURUM; NEUTROPENIA; NONHUMAN; OPPORTUNISTIC INFECTION; OUTCOMES RESEARCH; PNEUMOCYSTIS PNEUMONIA; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATITIS; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SALMONELLA; SINUSITIS; SMOKING CESSATION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIA; SUPERINFECTION; TOXOPLASMOSIS; VIRUS TRANSMISSION;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BACTERIAL INFECTIONS; CLINICAL TRIALS; HIV INFECTIONS; HUMANS;

EID: 27744524262     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/A3Q4-UQQN-X9EN-Y4HE     Document Type: Review

References (86)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-860.
2. Ledergerber B, Egger M, Erard V, et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA. 1999;282:2220-2226.
3. Godofsky EW, Zinreich J, Armstrong M, et al. Sinusitis in HIV-infected patients: a clinical and radiographic review. Am J Med. 1992;93:163-170.
4. Berger BJ, Hussain F, Roistacher K. Bacterial infections in HIV infected patients. Infect Dis Clin North Am. 1994;8:449-465.
5. Armstrong M Jr, McArthur JC, Zinreich SJ. Radiographic imaging of sinusitis in HIV infection. Otolaryngol Head Neck Surg. 1993;108:36-43.
6. Janoff EN, Breiman RF, Daley CL, Hopewell PC. Pneumococcal disease during HIV infection. Epidemiologic, clinical, and immunologic perspectives. Ann Intern Med. 1992;117:314-324.
7. Hirschtick RE, Glassroth J, Jordan MC, et al. Bacterial pneumonia in persons infected with the human immunodeficiency virus. Pulmonary Complications of HIV Infection Study Group. N Engl J Med. 1995;333:845-851.
8. Rubin JS, Honigberg R. Sinusitis in patients with the acquired immunodeficiency syndrome. Ear Nose Throat J. 1990;69:460-463.
9. DiRienzo AG, van Der Horst C, Finkelstein DM, Frame P, Bozzette SA, Tashima KT. Efficacy of trimethoprimsulfamethoxazole for the prevention of bacterial infections in a randomized prophylaxis trial of patients with advanced HIV infection. AIDS Res Hum Retroviruses. 2002;18:89-94.
10. Currier JS, Williams P, Feinberg J, et al. Impact of prophylaxis for Mycobacterium avium complex on bacterial infections in patients with advanced human immunodeficiency virus disease. Clin Infect Dis. 2001;32:1615-1622.
11. Chow JH, Stern JC, Kaul A, Pincus RL, Gromisch DS. Head and neck manifestations of the acquired immunodeficiency syndrome in children. Ear Nose Throat J. 1990;69:416-419, 422-423.
12. Godofsky EW, Zinreich J, Armstrong M, Leslie JM, Weikel CS. Sinusitis in HIV-infected patients: a clinical and radiographic review. Am J Med. 1992;93:163-170.
13. Lebovics RS, Stern JC, Kimmelman C. AIDS and otolaryngology: 1990 update part 1. Ear Nose Throat J. 1990;69:374-423.
14. Milgrim LM, Rubin JS, Rosenstreich DL, Small CB. Sinusitis in human immunodeficiency virus infection: typical and atypical organisms. J Otolaryngol. 1994;23:450-453.
15. Shah RM, Gupta S, Angeid-Backman E, O'Donnell J. Pneumococcal pneumonia in patients requiring hospitalization: effects of bacteremia and HIV seropositivity on radiographic appearance. Am J Roentgenol. 2000; 175:1533-1536.
16. White S, Tsou E, Waldhorn R, et al. Life threatening bacterial pneumonia in homosexuals with laboratory features of the acquired immunodeficiency syndrome. Chest. 1985;87:486.
17. Magnenat J, Nicod LP, Auckenthaler R, et al. Mode of presentation and diagnosis of bacterial pneumonia in human immunodeficiency virus-infected patients, Am Rev Respir Dis. 1991;144:917.
18. De Pinho AM, Lopes GS, Ramos-Filho CF, et al. Urinary tract infection in men with AIDS. Genitourinary Med. 1994;70:30-34.
19. Leport C, Rousseau F, Perronne C, Salmon D, Joerg A, Vilde JL. Bacterial prostatitis in patients infected with the human immunodeficiency virus. J Urol. 1989;141:334-336.
20. Rolston KV, Radentz S, Rodriguez S. Bacterial and fungal infections in patients with the acquired immunodeficiency syndrome. Cancer Detect Prev. 1990;14:377-381.
21. Tumbarello M, Tacconelli E, Donati KG, et al. HIV-associated bacteremia: how it has changed in the highly active antiretroviral therapy (HAART) era. J Acquir Immune Defic Syndr. 2000;23:145-151.
22. Dworkin MS, Ward JW, Hanson DL, Jones JL, Kaplan JE. Adult and adolescent spectrum of HIV disease project. Pneumococcal disease among human immunodeficiency virus-infected persons: incidence, risk factors, and impact of vaccination. Clin Infect Dis. 2001;32:794-800.
23. Redd SC, Rutherford GW 3rd, Sande MA, et al. The role of human immunodeficiency virus infection in pneumococcal bacteremia in San Francisco residents. J Infect Dis. 1990;162:1012-1017.
24. Gebo KA, Moore RD, Keruly JC, Chaisson RE. Risk factors for pneumococcal disease in HIV-infected patients. J Infect Dis. 1996;173:857-862.
25. Steinhart R, Reingold AL, Taylor F, Anderson G, Wenger JD. Invasive Haemophilus influenzae infections in men with HIV infection. JAMA. 1992;268:3350-3352.
26. Schlamm HT, Yancovitz SR. Haemophilus influenzae pneumonia in young adults with AIDS, ARC, or risk of AIDS. Am J Med. 1989;86:11-14.
27. Cordero E, Pachon J, Rivero A, et al. Haemophilus influenzae pneumonia in human immunodeficiency virus-infected patients. Clin Infect Dis. 2000;30:461-465.
28. Mendelson MH, Gurtman A, Szabo S, et al. Pseudomonas aeruginosa bacteremia in patients with AIDS. Clin Infect Dis. 1994;18:886-895.
29. Dropulic LK, Leslie JM, Eldred LJ, Zenilman J, Sears CL. Clinical manifestations and risk factors of Pseudomonas aeruginosa infection in patients with AIDS. J Infect Dis. 1995;171:930-937.
30. Shepp DH, Tang IT, Ramundo MB, Kaplan MK. Serious Pseudomonas aeruginosa infection in AIDS. J Acquir Immune Defic Syndr. 1994;7:823-831.
31. Vidal F, Mensa J, Martinez JA, et al. Pseudomonas aeruginosa bacteremia in patients infected with human immunodeficiency virus type 1. Eur J Clin Microbiol Infect Dis. 1999;18:473-477.
32. Baron AD, Hollander H. Pseudomonas aeruginosa bronchopulmonary infection in late human immunodeficiency virus disease. Am Rev Respir Dis. 1993;148(4 Pt 1):992-996.
33. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep. 1992;41:1-19.
34. Kaul D, Coffey MJ, Phare SM, Kazanjian P. Capacity of neutrophils and monocytes from human immunodeficiency virus-infected patients and healthy controls to inhibit growth of Mycobacterium bovis. J Lab Clin Med. 2003;141(5):330-334.
35. Smith K, Skelton H, Yeager J, et al. Cutaneous findings in HIV-1 positive patients: a 42 month prospective study. J Am Acad Dermatol. 1994;31:746-753.
36. Rieg G, Daar E, Witt M, et al. Community-acquired methicillin-resistant Staphylococcus aureus colonization among HIV-infected men who have sex with men: a point prevalence survey. In: Abstracts from the 12th Retroviral Conference; February 2005; Boston, MA. Abstract 877.
37. Hardy WD, Feinberg J, Finkelstein DM, et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021. N Engl J Med, 1992;327:1842-1848.
38. Buskin SE, Newcomer LM, Koutsky LA, Hooton TM, Spach DH, Hopkins SG. Effect of trimethoprim-sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis on bacterial illness, Pneumocystis carinii pneumonia, and death in persons with AIDS. J Acquir Immune Defic Syndr Human Retrovirol. 1999;20:201-206.
39. Navin TR, Rimland D, Lennox JL, et al. Risk factors for community-acquired pneumonia among persons infected with human immunodeficiency virus. J Infect Dis. 2000;181:158-164.
40. Edge MD, Rimland D. Community-acquired bacteremia in HIV-positive patients: protective benefit of co-trimoxazole. AIDS. 1997;10:1635-1639.
41. Murri R, Ammassari A, Pezzotti P, et al. Incidence and determinants of bacterial infections in HIV-positive patients receiving anti-Pneumocystis carinii/Toxoplasma gondii primary prophylaxis within a randomized clinical trial. J Acquir Immune Defic Syndr. 2001;27:49-55.
42. Podzamczer D, Salazar A, Jimenez J, et al. Intermittent trimethoprim-sulfamethoxazole compared with dapsonepyrimethamine for the simultaneous primary prophylaxis of Pneumocystis pneumonia and toxoplasmosis in patients infected with HIV. Ann Intern Med. 1995;122(10):755-761.
43. Wallace JM, Hansen NI, Lavange L, et al. Respiratory disease trends in the pulmonary complications of HIV infection study cohort. Pulmonary complications of HIV Infection Study Group. Am J Respir Crit Care Med. 1997;155(1):72-80.
44. Omenaca C, Turett G, Yarrish R, et al.. Bacteremia in HIV-infected patients: short-term predictors of mortality. J Acquir Immune Defic Syndr. 1999;22(2):155-160.
45. Anglaret X, Chene G, Attia A, et al. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Cote d'Ivoire; a randomised trial. Cotrimo-CI Study Group. Lancet. 1999;353:1463-1468.
46. Wiktor SZ, Sassan-Morokro M, Grant AD, et al. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1 infected patients with tuberculosis in Abidjan, Cote d'Ivoire: a randomized controlled trial. Lancet. 1999;353:1469-1475.
47. Mermin J. Lule J. Ekwaru JP, et al. Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet. 2004;346:1428-1434.
48. Centers for Disease Control. Guidelines for prophylaxis against Pneumocystis carinii pneumonia for persons infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep. 1989;38(suppl 5):1-9.
49. Martin JN, Rose DA, Hadley WK, et al. Emergence of Trimethoprim-Sulfamethoxazole resistance in the AIDS era. J Infect Dis. 1999;180:1809-1818.
50. Boumis E, Petrosillo N, Girardi E, et al. Changing patterns in the etiology of HIV-associated bacterial pneumonia in the era of highly active antiretroviral therapy. Eur J Clin Microbiol Infect Dis. 2001;20:71-73.
51. Jordano Q, Falco V, Almirante B, et al. Invasive pneumococcal disease in patients infected with HIV: still a threat in the era of highly active antiretroviral therapy. Clin Infect Dis. 2004;38:1623-1628.
52. Wininger DA, Fass RJ. Impact of Trimethoprim-Sulfamethoxazole prophylaxis on etiology and susceptibilities of pathogens causing HIV-associated bacteremia. Antimicrob Agents Chemother. 2002;46:594-597.
53. Feldman C, Glatthaar M, Morar R, et al. Bacteremic pneumococcal pneumonia in HIV-seropositive and HIV-seronegative adults. Chest. 1999;116:107-114.
54. Havlir DV, Dube MP, Sattler FR, et al. for the California Collaborative Treatment Group. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. N Engl J Med. 1996;335:392-398.
55. 2001 USPHS/IDSA Guidelines for the prevention of the opportunistic infections for HIV-infected adults. http://aidsinfo.nih.gov/guidelines/op_infections/OI_112801.pdf
56. Nuorti JP, Butler JC, Gelling L, Kool, JL, Reingold AL, Vugia DJ. Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California. Ann Intern Med. 2000;132:182-190.
57. Pierce AB, Hoy JF. Is the recommendation for pneumococcal vaccination of HIV patients evidence based? J Clin Virol. 2001;22:255-261.
58. De Gaetano Donati K, Bertagnoli S, Tumbarello M, et al. Effect of HAART on the incidence of bacterial pneumonia in HIV-infected subjects. Int J Antimicrob Agents. 2000;16:357-360.
59. Paul S, Gilbert HM, Lande L, et al. Impact of antiretroviral therapy on decreasing hospitalization rates of HIV-infected patients in 2001. AIDS Res Hum Retroviruses. 2002;18: 501-506.
60. Paul S, Gilbert HM, Ziecheck W, Jacobs J, Sepkowitz KA. The impact of potent antiretroviral therapy on the characteristics of hospitalized patients with HIV infection. AIDS. 1999;13:415-418.
61. Meynard JL, Guiguet M, Fonquernie L, et al. Impact of highly active antiretroviral therapy on the occurrence of bacteraemia in HIV-infected patients and their epidemiologic characteristics. HIV Med. 2003;4:127-132.
62. Sullivan JH, Moore RD, Keruly JC, Chaisson RE. Effect of antiretroviral therapy on the incidence of bacterial pneumonia in patients with advanced HIV infection. Am J Respir Crit Care Med. 2000;162:64-67.
63. Floris-Moore M, Lo Y, Klein RS, et al. Gender and hospitalization patterns among HIV-infected drug users before and after the availability of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2003;34:331-337.
64. Hughes WT, Danker WM, Yogev R, et al. Comparison of atovaquone and azithromycin with trimethoprim-sulfamethoxazole for the prevention of serious bacterial infections in children with HIV infection. Clin Infect Dis. 2005;40:136-145.
65. ART Cohort Collaboration. Prognostic importance of initial response in HIV-1 infected patients starting patent antiretroviral therapy: analysis of prospective studies. Lancet. 2003;362:679-686.
66. Raffanti SP, Fusco JS, Sherrill BH, et al. Effect of persistent moderate viremia on disease progression during HIV therapy. J Acquir Immune Defic Syndr. 2004;37:1147-1154.
67. Olsen CH, Gatel J, Ledergerber B, et al. Risk of AIDS and death at given HIV-RNA and CD4 cell counts, in relation to specific antiretroviral drugs in the regimen. AIDS. 2005;19:319-330.
68. Wolff AJ, O'Donnell AE. Pulmonary manifestations of HIV infection in the era of highly active antiretroviral therapy. Chest. 2001;120:1888-1893.
69. Lopez-Palomo C, Martin-Zamorano, M. Benitez E, et al. Pneumonia in HIV-infected patients in the HAART era: incidence, risk, and impact of the pneumococcal vaccination. J Med Virol. 2004;72:517-524.
70. Currier JS, Williams PL, Koletar SL, et al. Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. A randomized, double-blind, placebo-controlled trial. AIDS Clinical Trials Group 362 Study Team. Ann Intern Med. 2000;133:493-503.
71. Koletar SL, Heald AE, Finkelstein D, et al. ACTG 888 Study Team. A prospective study of discontinuing primary and secondary Pneumocystis carinii pneumonia prophylaxis after CD4 cell count increase to >200 × 106/I. AIDS. 2001;15:1509-1515.
72. Ledergerber B, Mocroft A, Reiss P, et al. Eight European Study Groups. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. N Engl J Med. 2001;344:168-174.
73. Lopez Bernaldo de Quiros JC, Miro JM, Pena JM, et al. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. N Engl J Med. 2001;344:159-167.
74. Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA. 2004;292:251-265.
75. Garcia F, de Lazzari E, Plana M, et al. Long-term CD4 T cell response to highly active antiretroviral therapy according to baseline CD4 T cell count. J Acquir Immune Defic Syndr. 2004;36:702-713.
76. Paredes R, Mocroft A, Kirk O, et al. Predictors of virologic success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe. Arch Intern Med 2000;160:1123-1132.
77. Madhi SA, Petersen K, Khoosal M et al. Reduced effectiveness of Hemophilus influenzae type b conjugate vaccine in children with a high prevalence of human immunodeficiency virus type 1 infection. Pediatr Infect Dis J. 2002;21:315-321.
78. Spoulou VI, Tsoumas DL, Papaevangelou VG, Mostrou GI, Theodoridou MC. Haemophilus influenzae type b conjugate vaccine-induced immunological memory in symptomatic HIV-1-infected children. AIDS. 2003;17:1396-1398.
79. Centers for Disease Control and Prevention. Recommendations of the immunization Practices Advisory Committee. MMWR Morb Mortal Wkly Rep. 1989;38:64-68, 73-76.
80. Centers for Disease Control and Prevention. Recommendations of the immunization Practices Advisory Committee. MMWR Morb Mortal Wkly Rep. 1997;46:1-24.
81. Ward JW, Hanson DL, Jones J, Kaplan J. Pneumococcal vaccination and the incidence of pneumonia among HIV infected people. Clin Infect Dis. 1996;23:905.
82. Centers for Disease Control and Prevention. USPHS/IDSA Guidelines for the prevention of opportunistic infections in people infected with HIV. MMWR Morb Mortal Wkly Rep. 1999;48:1-66.
83. Ahmed F, Steinhoff MC, Rodriguez-Barradas MC, et al. Effect of human immunodeficiency virus type 1 infection on the antibody response to a glycoprotein conjugate pneumococcal vaccine: results from a randomized trial. J Infect Dis. 1996;173:83-90.
84. Kroon FP, van Dissel JT, Ravenbergen E, et al. Enhanced antibody response to pneumococcal polysaccharide vaccine after prior immunization with conjugate pneumococcal vaccine in HIV-infected adults. Vaccine. 2001;19:886-894.
85. Feikin DR, Elie CM, Goetz MB, et al. Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults. Vaccine. 2001;20:545-553.
86. Cohn DL, Breese PS, Burman WJ, et al. Continued benefit from HAART: trends in AIDS-related opportunistic illnesses in a public health care system, 1990-2001. In: Abstracts from the XIV International AIDS Conference; 2002; Barcelona, Spain. Abstract ThOrC1443.